Navigation Links
ChanTest Announces a Global Campaign to Share New Findings and Developments in Cystic Fibrosis Research
Date:9/11/2013

Cleveland, OH (PRWEB) September 11, 2013

The world is still looking for meaningful solutions to address the pain and suffering of patients with Cystic Fibrosis. On Thursday, September 12, ChanTest will be hosting a complimentary webinar entitled “Unfolding Cystic Fibrosis Research,” to share important information in this field.

The event will include presentations by Dr. Jinliang Sui, Senior Director of High Throughput Screening and Bioinformatics at Flatley Discovery Lab, where they are seeking a Cure for Cystic Fibrosis, and Dr. Anthony Lacerda, Director of Contract Research and Development at ChanTest.

Dr. Sui will discuss efforts at Flatley Discovery Lab to advance high throughput screening for CFTR modulators (cystic fibrosis transmembrane conductance regulator) using human epithelial (skin) cells. Scientists there have identified novel and efficacious drugs called CFTR modulators, which they are planning to take into clinical trials to be evaluated for patients.

Dr. Lacerda will then present data from the ChanTest Ussing Chamber Assay (UCA) research. This research allows scientists like Dr. Sui at Flatley Discovery Lab to assess a new drug’s effects on proteins such as CFTR. This expedites the process of finding the best new drug compounds because the ChanTest Ussing Chamber Assay provides faster answers, and more accurate answers.

“In a cystic fibrosis (CF) patient, the CF gene tells the individual’s epithelial cells to produce a defective version of the CFTR (cystic fibrosis transmembrane conductance regulator) protein, which then causes the fluid and mucus found in cells that line the lungs (and other organs) to become thickened and sticky,” said Dr. Lacerda of ChanTest. “By being able to identify the best drug candidates that can have an effect on CFTR, through the Ussing Chamber Assay from ChanTest, we are able to significantly shorten our evaluation process, saving both time and money.”

We invite everyone interested in helping to share these new developments and findings, to join the webinar.

Webinar: Unfolding Cystic Fibrosis Research
DATE: Thursday, September 12, 2013
TIME: 1 p.m. ET
DURATION: 1 hour
REGISTER

About ChanTest – The Ion Channel Expert

ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the CRO has tested compounds for more than 300 global pharmaceutical and biotechnology companies, and partners with them to speed the drug development process for the release of better, safer drugs.

ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines, and nonclinical cardiac risk assessment service portfolio, is the most comprehensive commercially available today.

Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in independent surveys since 2006. ChanTest is based in Cleveland, Ohio. For more information, e-mail info(at)chantest(dot)com or visit http://www.chantest.com to learn more about what we do.

To learn more about the ChanTest® ChansPorter™ Assays, click here.

FURTHER INFORMATION
ChanTest
14656 Neo Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
1-216-332-1665 Tel
1-216-332-1706 Fax
info(at)chantest(dot)com

Contact for Media Inquiries:
Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer
cmathes(at)chantest(dot)com
http://www.chantest.com

Read the full story at http://www.prweb.com/releases/2013/9/prweb11078923.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. ChanTest Announces Third User Meeting: Partnerships in Drug Discovery
2. ChanTest Announces ChansPorter™ Assays to Accelerate Drug Development for Cystic Fibrosis Patients
3. Diet Doc Announces Improved Medical Diet Plans That Help Patients Avoid Excess Weight Gain, Now Found to Possibly be Caused by Antidepressant Medication
4. AxoGen, Inc. Announces Exercise of Over-Allotment Option
5. Bell Lifestyle Products Inc. Announces the Launch of Two New Natural Health Products
6. Contract Research Organization WCCT Global Announces Acquisition of Early Phase Ophthalmology and Aesthetics Capabilities
7. Native Remedy; Zion Health Announces Natural Hair Products for Color Treated Hair: Adama Minerals Now Available at Whole Foods Market in West Hartford, CT
8. Northern New Jersey Water Softener Company Announces Water Softener Trade-In Deal for Home and Business Owners
9. ITAZ Technologies Announces a Discount on its Sohodox Document Software at BitsDuJour
10. American Telemedicine Association Announces Insurance Brokerage Partnership with HUB Healthcare Solutions
11. Game Ready(R) Announces Launch of Kineta(TM) and Kineta(TM) Cool Post-Op Knee Braces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases ... evaluation of DataPoint’s team dedication and commitment to the SharePoint ecosystem. A ... annual list. The panel’s goal is to recognize and promote technology entrepreneurship. , ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Be ... new office in the heart of Old Town at 108 South Columbus St, Suite ... businesses the highest level of medical care in the convenience of their homes, offices ...
(Date:2/11/2016)... ... February 11, 2016 , ... Hoggan ... force gauges used in physical therapy, occupational therapy and sports medicine clinics, hospitals, ... cord exercise and therapy, introduces its new microFET Digital Pinch Gauge. , ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... become more actively engaged in health and wellness best practices in the past ... riding this trend. February is American Heart Month, which acts as an exceptional ...
(Date:2/11/2016)... ... February 11, 2016 , ... Research led by Providence ... several common cancer screenings, especially among women. Cancer screenings are often the best ... , The study,“What Does Medicaid Expansion Mean for Cancer Screening and Prevention: Results ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... India , February 11, 2016 ... Global Autoclave Market Report 2016 research report provides ... key regions, development status with crucial statistical data ... --> http://www.deepresearchreports.com/142870.html . --> Complete ... profiling 19 companies and supported with 296 tables ...
(Date:2/10/2016)... Feb. 11, 2016  QT Vascular Ltd., together with ... together with its subsidiaries, the "Group"), is pleased ... with AngioScore, Inc. ("ÄngioScore") (now owned by Spectranetics ... the United States Court of ... reversed an earlier district court order (the "DCO").   ...
(Date:2/10/2016)... Inc. (Nasdaq: GHDX ) today reported financial results and ... --> --> Revenue was $74.5 ... in the fourth quarter of 2014, an increase of 8 percent. ... the same period in the prior year. --> ... fourth quarter of 2015, an increase of 9 percent compared with ...
Breaking Medicine Technology: